Comparative Analysis of Bleeding Frequency and Factor Utilization in Severe Hemophilia A and Hemophilia B Patients: Implications for Clinical Phenotype Variability

Abstract

In haemophilia A and B, blood coagulants are reduced because of X-linked genetic factors. A study found that severe Haemophilia A (HA) tends to have a higher Hemophilia Severity Score (HSS) than severe Haemophilia B (HB). HA and HB patients were compared in terms of bleeding frequency and factor utilization. The data were collected from the records of our Haemophilia Clinic in a retrospective study conducted within a single institution. Hemophilia A and Haemophilia B were diagnosed in 88 and 16 subjects, respectively. A plasma-derived factor concentrate was administered on-demand to all of the patients. In this study, Chi-square, Man-Whitney U, and one-sample T tests were used. Version 12.1.4 of MedCalc Statistical Software was used for all calculations. Haemophilia A patients were admitted at a rate of 3.125 patients per year, while Haemophilia B patients were admitted at a rate of 0.77 patients per year (P 0.05). For haemophilia A patients, 3731500IU of FVIII (21201.704IU/patient/year) was used, whereas for haemophilia B patients, 611000IU of Factor IX (17457.142IU/patient/year) was used. The factor concentrations did not differ statistically significantly (P = 0.57). This study suggests Hemophilia A and Hemophilia B are inherited coagulation disorders that are clinically distinctive that differs depending on the severity of the disease. A recent study similar to ours also found results that are in agreement with ours.